PepGen Inc. (PEPG)
NASDAQ:PEPG
PEPG Stock Chart & Stats
$1.64
-$0.11(-3.01%)
At close: 4:00 PM EST
$1.64
-$0.11(-3.01%)
Day’s Range― - ―
52-Week Range$1.01 - $7.80
Previous CloseN/A
Volume7.67K
Average Volume (3M)6.68M
Market Cap
$113.35M
Enterprise Value$73.29M
Total Cash (Recent Filing)$148.46M
Total Debt (Recent Filing)$17.00M
Price to Earnings (P/E)―
Beta0.70
Next Earnings
May 07, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding69,115,295
10 Day Avg. Volume930,736
30 Day Avg. Volume6,679,177
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.86
Price to Sales (P/S)0.00
P/FCF Ratio-3.36
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-52.47
Enterprise Value/Ebitda-0.79
Forecast
1Y Price Target
$10.33Price Target Upside529.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pharmacokinetics And Dose EscalationMuscle tissue measurements confirmed robust drug accumulation consistent with the pharmacokinetic model, supporting the potential for higher doses to increase target engagement.
Safety ProfileSafety data reported no serious adverse events, no kidney-related treatment-emergent adverse events, and no cumulative albumin signal across doses, supporting tolerability of the program.
Trial Execution And FinancingManagement reiterated sufficient financial runway and indicated that higher-dose cohorts can be recruited and dosed at ex‑US sites, supporting completion of key readouts and preserving trial timelines.
Bears Say
Clinical Safety SignalsUnblinded safety data revealed transient decreases in kidney function and temporary increases in albumin at higher doses, introducing clinical risk that could deter physicians and complicate the regulatory pathway.
Preclinical Safety And Analyst SkepticismPreclinical infusion-related effects observed in mice, combined with a prior clinical hold on a related program for electrolyte imbalance, raise concerns about safety readthroughs for similar molecular designs and sustain analyst caution.
Regulatory UncertaintyFDA placed a partial clinical hold on the FREEDOM2 trial after reviewing preclinical data, creating regulatory uncertainty and restricting progress in the US.
PepGen Inc. News
PEPG FAQ
What was PepGen Inc.’s price range in the past 12 months?
PepGen Inc. lowest stock price was $1.01 and its highest was $7.80 in the past 12 months.
What is PepGen Inc.’s market cap?
PepGen Inc.’s market cap is $113.35M.
When is PepGen Inc.’s upcoming earnings report date?
PepGen Inc.’s upcoming earnings report date is May 07, 2026 which is in 23 days.
How were PepGen Inc.’s earnings last quarter?
PepGen Inc. released its earnings results on Mar 04, 2026. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.353 by $0.083.
Is PepGen Inc. overvalued?
According to Wall Street analysts PepGen Inc.’s price is currently Undervalued.
Does PepGen Inc. pay dividends?
PepGen Inc. does not currently pay dividends.
What is PepGen Inc.’s EPS estimate?
PepGen Inc.’s EPS estimate is -0.29.
How many shares outstanding does PepGen Inc. have?
PepGen Inc. has 69,115,295 shares outstanding.
What happened to PepGen Inc.’s price movement after its last earnings report?
PepGen Inc. reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.353. Following the earnings report the stock price went down -18.565%.
Which hedge fund is a major shareholder of PepGen Inc.?
Currently, no hedge funds are holding shares in PEPG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PepGen Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.33 (529.88% Upside)
$10.33 (529.88% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.4%
Last 30 Days ▲ 15.2%
Last 30 Days ▲ 15.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-44.87%
12-Months-Change
Fundamentals
Return on Equity
-75.73%
Trailing 12-Months
Asset Growth
15.26%
Trailing 12-Months
Company Description
PepGen Inc.
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
PEPG Stock 12 Month Forecast
Average Price Target
$10.33
▲(529.88% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
―
Lyell Immunopharma
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
Currently, No data available
---